From kentucky.com
()
 |
Invalid News Story. |
CEO Peter Dolan
CEO Peter Dolan has been the chief executive officer of Bristol-Myers Squibb Co since 2001. He is 50 years old. Follow Mr. Dolan and Bristol-Myers Squibb Co in the news and blogs or share your own opinion about the company and its... [more]
CEO Peter Dolan has been the chief executive officer of Bristol-Myers Squibb Co since 2001. He is 50 years old. Follow Mr. Dolan and Bristol-Myers Squibb Co in the news and blogs or share your own opinion about the company and its leadership.
News
Showing:
Top Stories
-
Archive
The state of Alabama has settled Medicaid drug pricing lawsuits it filed against drugmaker Bristol-Myers Squibb and four other companies.A lawyer representing the state, Jere Beasley, confirmed Friday the settlement has been reached.Bristol-Myers Squibb is one of more than 70 companies the state...
- Bristol-Myers Squibb outsources IT (zdnet.com.au)
- Fitch Affirms Bristol-Myers Squibb Co.'s IDR at 'A+'; Outlook Stable (news.google.com)
- Bristol-Myers Squibb to Commence Cash Tender Offer for ImClone ... (news.google.com)
On Tuesday, October 14, Bristol-Myers Squibb Company and Capital Health System will host a community health fair to raise awareness about the importance of diagnosing and treating chronic diseases and provide ...
- Bristol-Myers Squibb hires Wyeth executive for Devens plant (boston.bizjournals.com)
- Bristol-Myers Squibb Submits Letter to ImClone Board of Directors (centredaily.com)
Based on the aggregated intelligence of 115,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, pharmaceutical giant Bristol-Myers Squibb has earned a respected four-star ...
More perspectives...
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Merrill+Lynch+Upgrades+Bristol-Myers+Squibb+%28BMY%29+to+Buy/4051310.html for the full story.
From streetinsider.com
()
- NYU Cancels Merrill Lynch Resume Workshop (consumerist.com)
- Merrill Lynch's Trading Lock Of The Week: Sell Merrill Lynch (247wallst.com)
- MERRILL LYNCH - Neues Verkaufssignal droht (godmode-trader.de)
WinnerELI LILLY TO ACQUIREIMCLONE SYSTEMSIndianapolis-based Lilly has agreed to spend more than $6 billion to fortify its cancer treatment portfolio by acquiring the biotechnology firm in a deal that tops earlier offers from competitor Bristol-Myers Squibb Co. Lilly shares fell $2.89 to $38.42...
More perspectives...
From TheState.com
()
A Manhattan federal judge has ruled that the U.S. Supreme Court’s recent ruling in Stoneridge Investment Partners v. Scientific-Atlanta Inc., doesn’t shield a Bristol-Myers Squibb Co. executive from securities fraud claims. The executive made no public statements, but his behavior was central to...
More perspectives...
From jlbreport.com
()
GlaxoSmithKline, Johnson & Johnson, Merck & Co. and Bristol-Myers Squibb Co. have all started more flexible, focused units to some extent.
More perspectives...
From news.google.com via
Google News.
()
Eli Lilly (LLY) will acquire ImClone Systems (IMCL) for $70 per share or about $6.5 billion in cash.The price is about 7.7% above Friday’s close and about 51% above the stock price in July before Bristol-Myers announced its takeover bid. ImClone had previously rejected two bids by Bristol-Myers...
More perspectives...
From minyanville.com
()
The ‘mystery buyer’ waiting to pounce on biotech firm ImClone has been revealed as Eli Lilly.
Lilly has trumped rival firm Bristol-Myers Squibb with an offer of $70 per share, or $6.5 billion all told. The offer has been approved by the directors of both companies. In the month before Bristol...
More perspectives...
From blogs.nature.com
()
BOSTON/PHILADELPHIA (Reuters) - Eli Lilly and Co (nyse: LLY - news - people ) has agreed to acquire ImClone Systems Inc (nasdaq: IMCL - news - people ) for $6.5 billion, outbidding Bristol-Myers Squibb Co (nyse: BMY - news - people ) and probably ...
More perspectives...
From search.live.com via
Windows Live.
()
BOSTON/PHILADELPHIA, Oct 6 (Reuters) - Eli Lilly and Co(LLY.N: Quote , Profile , Research , Stock Buzz ) has agreed to acquire ImClone Systems Inc (IMCL.O: Quote , Profile , Research , Stock Buzz ) for $6.5 billion, outbidding Bristol-Myers Squibb Co ...
More perspectives...
From search.live.com via
Windows Live.
()
Oct. 6 (Bloomberg) -- Eli Lilly & Co. agreed to buy ImClone Systems Inc ., the biotechnology company controlled by billionaire Carl Icahn , for $6.5 billion, and Bristol-Myers Squibb Co . said it would drop its hostile bid of $62 a share. Investors ...
More perspectives...
From search.live.com via
Windows Live.
()
... but other compounds, including IMC-11F8, under development by ImClone to which Bristol-Myers Squibb holds long-term marketing rights. ...
More perspectives...
From news.google.com via
Google News.
()
After rejecting Bristol-Myers Squibb's sweetened offer of $4.7 billion at $62 a share, ImClone is in advanced talks with the mystery suitor npw identified as Eli Lilly & Co, which has made an offer of $70 a ...
More perspectives...
From rss.topix.net via
Topix.
()
PRINCETON Bristol-Myers Squibb has announced that the Food and Drug Administration has approved the use of a new drug, REYATAZ, a once-daily boosted with ritonavir as part of combination therapy in previously ...
More perspectives...
You can improve this news page by changing its keywords and content sources.
Edit News
Edit News
People in Pictures
Top Money Articles
 |
Bernanke sees no repeat of `70s-style inflation
Well, he didn't see the housing bubble or subprime credit crunch either...
|
 |
Smart ways to buy a PDA
You should not confuse your career with your life.
|
 |
Flavio Briatore Hooks Up With Yet Another Supermodel
Flavio is one lucky Italian businessman. This time he's ringing wedding bells.
|
Popular Money Zines
